Long-circulating liposomes (also known as stealth liposomes) are lipid based nanoparticles that have been extensively studied as drug delivery system for the treatment of cancers. Liposomal drugs improve the outcome of treatment mainly via 1) increasing the amount of drugs accumulated at tumor sites, and 2) decreasing the systemic toxicity that is associated with free drugs. In this application, we propose to further improve current liposomal vectors (stealth liposomes) to facilitate the drug release selectively at the tumor site, leading to an improvement in the bioavailability of chemotherapeutic drugs and thus a further enhancement in anti-tumor activity. Design of this novel, target-sensitive nanodelivery system is based on the following discoveries that: 1) ?PA is a serine protease that selectively recognizes and cleaves specific peptide sequences; 2) ?PA is overexpressed with remarkable consistency in many types of malignant human tumors including prostate cancer; 3) mouse or human group X secreted phospholipase A2 (sPLA2-X) is highly efficient in hydrolyzing phosphatidylcholine-rich vesicles; and 4) sPLA2-X is synthesized as an inactive proenzyme and becomes activated after the pro-peptide is enzymatically cleaved from the N-terminal end. We propose to generate and incorporate into the surface of liposomes a fusion protein in which a pro-peptide is coupled to sPLA2-X at the N-terminus via a ?PA-sensitive linkage. Such modification is expected to result in inactivation of the enzyme. We hypothesize that sPLA2-X pro-enzyme, upon co-delivery to the tumors with drug-encapsulated liposomes, will be activated by ?PA, resulting in degradation of the liposomes, selective release of the encapsulated drugs at the tumor site, and efficient killing of tumor cells. Accordingly, specific aims of this application are:
Aim 1 : To develop a ?PA-sensitive liposomal doxorubicin (DOX) and characterize its biophysical and pharmacological properties in vitro.
Aim 2 : To study the distribution and therapeutic effect of ?PA-sensitive liposomal DOX in an animal tumor model. Successful completion of these studies will lead to development of novel liposomal drugs that will advance the treatment of ?PA-positive cancers. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA128415-02
Application #
7454327
Study Section
Special Emphasis Panel (ZRG1-BCMB-S (51))
Program Officer
Fu, Yali
Project Start
2007-07-01
Project End
2010-06-30
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
2
Fiscal Year
2008
Total Cost
$148,500
Indirect Cost
Name
University of Pittsburgh
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Lu, Jianqin; Huang, Yixian; Zhao, Wenchen et al. (2013) PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers. Biomaterials 34:1591-600
Zhang, Xiaolan; Lu, Jianqin; Huang, Yixian et al. (2013) PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel. Bioconjug Chem 24:464-72
Zhang, Peng; Huang, Yixian; Makhov, Alexander M et al. (2013) Characterization of spherulites as a lipidic carrier for low and high molecular weight agents. Pharm Res 30:1525-35
Lu, Jianqin; Huang, Yixian; Zhao, Wenchen et al. (2013) Design and characterization of PEG-derivatized vitamin E as a nanomicellar formulation for delivery of paclitaxel. Mol Pharm 10:2880-90
Huang, Yixian; Lu, Jianqin; Gao, Xiang et al. (2012) PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel. Bioconjug Chem 23:1443-51
Zhang, Yifei; Huang, Yixian; Zhang, Peng et al. (2012) Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells. Int J Nanomedicine 7:4473-85